Radiotherapy upstaged by testicular cancer drug
This article was originally published in Clinica
Executive Summary
The use of radiotherapy to treat the most common form of testicular cancer has received a blow with the publication today of the results of UK research into a drug application. The Medical Research Council (MRC)-funded study found that the platinum-based chemotherapy compound carboplatin outperforms, at least in the short-term, the standard form of treatment of stage I testicular cancer, radiotherapy.